Latest Commercialization News

Grand Gulf Energy has inked a non-binding MoU with Sage Potash to jointly explore helium and potash resources in Utah’s Paradox Basin, aiming to share costs and infrastructure for a 3D seismic survey and potential drilling.

Solstice Minerals has completed a major Reverse Circulation drilling campaign at its Yarri Project in Western Australia, targeting promising gold prospects with assay results expected soon.

MTM Critical Metals has locked in a pre-permitted industrial site in Texas, positioning itself to commission its innovative metal recovery plant by year-end 2025 and accelerate U.S. commercial expansion.

Livium has expanded its battery recycling partnership with BYD Australia, now covering commercial vehicle batteries and energy storage systems alongside electric vehicle batteries.

EP&T Global Limited reports a robust 10% increase in Annual Recurring Revenue to $14.9 million, driven by expanded site coverage and new contract wins across Europe and the UK.

New Murchison Gold Limited has reported impressive high-grade gold intercepts from shallow drilling at its Crown Prince Gold Project, suggesting a richer and thicker caprock resource than previously estimated.

Humm Group reported a solid 10% increase in assets under management to $5.3 billion for 3Q25, maintaining stable margins while advancing a new hybrid loan product and IT platform modernization.

New World Resources has announced a significant 25% increase in the Antler Copper Project's mineral resource to 14.2 million tonnes at 3.8% copper equivalent, with 88% now classified as measured and indicated, underpinning its path to production in 2027.

Universal Biosensors reports solid growth in its wine testing segment and outlines plans for a capital raise alongside the upcoming AQUASCOUT water testing device launch.

Universal Biosensors reported a 6% increase in revenue for Q1 2025 but posted a net loss of A$3.84 million, with cash reserves sufficient only through Q3 2025, raising questions about its financial sustainability.

Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.

Cleo Diagnostics has completed alpha testing of its ovarian cancer pre-surgical triage assay kits, confirming robust performance and differentiation between benign and malignant disease. The company now moves forward to assay optimisation and manufacturing scale-up, edging closer to FDA submission and commercial launch.